PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), which target the programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), have been approved in the United States, Japan, and other countries, for the treatment of non-small-cell lung cancer (NSCLC) patients.